Max Masucci
Stock Analyst at TD Cowen
(0.22)
# 4,137
Out of 4,748 analysts
28
Total ratings
16%
Success rate
-31.44%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $54.17 | +32.91% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $28.30 | -11.66% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $47.65 | +11.23% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $71.41 | +33.03% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $9.61 | +87.30% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $1.04 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $4.22 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $1.76 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $4.64 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $5.69 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.61 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.17 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.00 | +733.33% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $131.72 | +256.82% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.07 | +514.25% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20,000 → $17,500 | $0.22 | +7,954,445.45% | 5 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $54.89 | +164.16% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $54.17
Upside: +32.91%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $28.30
Upside: -11.66%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $47.65
Upside: +11.23%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $71.41
Upside: +33.03%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $9.61
Upside: +87.30%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.04
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.22
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.76
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.64
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.69
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.61
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.17
Upside: -
May 11, 2021
Initiates: Buy
Price Target: $25
Current: $3.00
Upside: +733.33%
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $131.72
Upside: +256.82%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $4.07
Upside: +514.25%
Nov 5, 2020
Maintains: Buy
Price Target: $20,000 → $17,500
Current: $0.22
Upside: +7,954,445.45%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $54.89
Upside: +164.16%